Rocket Pharmaceuticals (RCKT) Notes Payables (2014 - 2021)
Rocket Pharmaceuticals (RCKT) posted Notes Payables of $5.1 million for Q2 2021, up 2.33% sequentially from $5.0 million in Q1 2021.
Powered by 
Analysis
Rocket Pharmaceuticals (RCKT) Notes Payables (2014 - 2021) Analysis & Trends
Rocket Pharmaceuticals has reported Notes Payables for 3 years, with the latest figure at $5.1 million in Q2 2021.
- Quarterly Notes Payables changed N/A year-over-year to $5.1 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $5.1 million (changed N/A YoY) and the FY2020 annual result came in at $4.9 million, changed N/A from the prior year.
- Notes Payables improved to $5.1 million in Q2 2021 per RCKT's latest filing, from $5.0 million in the prior quarter.
- Over five years, Notes Payables peaked at $5.1 million in Q2 2021 and troughed at $4.8 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 5.10 Mn |
| Mar 31, 2021 | 4.99 Mn |
| Dec 31, 2020 | 4.88 Mn |
| Sep 30, 2020 | 4.77 Mn |
| Dec 31, 2014 | 3.06 Mn |